Daily desk

News

Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.

6 stories

Split cards contrast PATHFINDER 2's 60.3% positive predictive value against NHS-Galleri's missed primary endpoint, framed as "two trials, one blood test, different verdicts."
🩺 Health Study

Two Nature Medicine Trials of a Multi-Cancer Blood Test Reach Different Verdicts on the Same Day

Published the same day in Nature Medicine, PATHFINDER 2 and the NHS-Galleri trial reach different verdicts on GRAIL's Galleri blood test: s…

EduFabTech · 1h ago · 5 min read
A single IV infusion generates CAR T cells inside the body that clear CD19-positive B cells, in a 16-patient trial spanning four autoimmune diseases with mostly mild side effects.
🩺 Health Study

Single-Infusion In Vivo CAR T-Cell Therapy Eases Four Neurologic Autoimmune Diseases in Small NEJM Trial

A 16-patient trial published in NEJM on September 3, 2026 tested a single-infusion lentiviral vector that generates CD19 CAR T cells inside…

EduFabTech · 4d ago · 4 min read
A stylized bacteriophage docking on a drug-resistant bacterium illustrates the new consensus guideline, backed by stats on its 60+ recommendations, 20 organizations and 18 expert authors.
🩺 Health Report

First International Consensus Guideline for Personalized Phage Therapy Published in Nature Medicine

An international working group coordinated by Germany's DGI has published the first consensus guideline for personalized bacteriophage ther…

EduFabTech · 5d ago · 4 min read
A brainstem diagram highlights where diffuse midline glioma forms, alongside survival figures for children taking the epilepsy drug levetiracetam versus those who were not.
🩺 Health Study

A Common Epilepsy Drug Is Linked to Longer Survival in an Almost Untreatable Childhood Brain Tumor

A retrospective Nature Medicine study (Sept. 17, 2026) led by Stanford Medicine finds children with diffuse midline glioma survived longer …

EduFabTech · 18 Sep 2026 · 4 min read
A blood-drop icon holding ten microRNA markers plus CA19-9 illustrates the PANXEON score, alongside its 86.8% stage I-II sensitivity, 96.8% specificity, and 1,785-patient cohort.
🩺 Health Study

A Blood-Based Score Combining Ten microRNAs and CA19-9 Flags Early Pancreatic Cancer in a 1,785-Person Study

A prospective 1,785-person study published in Nature Medicine on September 16, 2026, found that PANXEON — a blood test combining ten microR…

EduFabTech · 17 Sep 2026 · 4 min read
A CD3×CD19 bispecific antibody bridges a patient's T cell and a B cell, with key trial results — 12 patients, 80% reaching low disease activity, 60% meeting remission criteria.
🩺 Health Study

Phase 1 Trial Finds a Cancer-Style T-Cell Engager Can Push Refractory Lupus Into Remission

A phase 1 trial of A-319, a CD3×CD19 bispecific antibody adapted from cancer therapy, pushed most of 12 treatment-resistant lupus patients …

EduFabTech · 16 Sep 2026 · 4 min read